WGU D116 Advanced Pharmacology
2026/2027 | Final Exam & Pre-Assessment
Questions, Answers & Detailed Rationales |
Updated Study Guide
WGU D116 ADVANCED PHARMACOLOGY 2026/2027
FINAL EXAM & PRE-ASSESSMENT | COMPREHENSIVE QUESTIONS
DOCUMENT OVERVIEW
• This comprehensive study guide contains detailed multiple-choice questions
designed to prepare you for the WGU D116 Advanced Pharmacology final exam
and pre-assessment, with complete rationales for each answer to reinforce
understanding and retention
• Use this material by reviewing questions systematically across all pharmacology
domains, focusing on areas where you score lowest, and referring to detailed
rationales to understand not just the correct answer but the clinical reasoning
behind it
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1-20)
1) Which of the following best describes bioavailability?
A) The amount of drug that reaches the systemic circulation in unchanged form
B) The time it takes for a drug to reach peak concentration
C) The volume of distribution of a drug in the body
D) The rate at which a drug is eliminated from the body
E) The ability of a drug to cross the blood-brain barrier
CORRECT ANSWER: A) The amount of drug that reaches the systemic
circulation in unchanged form
,RATIONALE: Bioavailability is defined as the percentage or fraction of administered
drug dose that reaches systemic circulation in unchanged (active) form. This is a
critical pharmacokinetic parameter that determines drug effectiveness. Option B
describes Tmax (time to maximum concentration), C refers to volume of
distribution, D pertains to clearance/elimination, and E relates to drug distribution
properties. Bioavailability is essential for predicting clinical efficacy and is
influenced by absorption, first-pass metabolism, and route of administration.
2) A 65-year-old male patient has a creatinine clearance of 25 mL/min. Which
pharmacokinetic parameter is most significantly affected in renal
impairment?
A) Absorption rate from the GI tract
B) Clearance and half-life of renally eliminated drugs
C) The volume of distribution of lipophilic drugs
D) The protein binding capacity of serum albumin
E) The first-pass metabolism rate
CORRECT ANSWER: B) Clearance and half-life of renally eliminated drugs
RATIONALE: In patients with renal impairment, the kidneys' ability to eliminate
drugs is compromised, directly reducing total body clearance. This results in
prolonged half-life and increased risk of drug accumulation. Patients with creatinine
clearance of 25 mL/min have severe renal impairment requiring significant dosage
adjustments or alternative medications. While absorption, Vd, protein binding, and
metabolism may be somewhat affected, the primary concern is reduced renal
clearance of active or toxic metabolites. Many drugs require dose reduction or
longer dosing intervals in renal failure.
3) Which of the following processes is responsible for the first-pass effect
when a drug is taken orally?
A) Hepatic metabolism before reaching systemic circulation
,B) Renal filtration at the glomerulus
C) Plasma protein binding in the bloodstream
D) Distribution to peripheral tissues
E) Biliary excretion into the intestines
CORRECT ANSWER: A) Hepatic metabolism before reaching systemic
circulation
RATIONALE: The first-pass effect (first-pass metabolism) occurs when an orally
administered drug is absorbed from the GI tract and transported via the portal
blood to the liver before entering the systemic circulation. Hepatic enzymes
(particularly the cytochrome P450 system) metabolize a portion of the drug,
reducing the amount of unchanged drug reaching systemic circulation. This is why
some drugs have very low oral bioavailability despite good absorption (e.g.,
nitroglycerin, which is given sublingually to bypass this effect). Renal filtration
occurs after systemic absorption, protein binding doesn't eliminate the drug,
distribution occurs after systemic circulation is reached, and biliary excretion is a
separate elimination pathway.
4) A drug has a volume of distribution (Vd) of 200 L in a 70 kg patient. What
does this indicate?
A) The drug is highly water-soluble and remains in the vascular space
B) The drug distributes extensively into tissues beyond the vascular compartment
C) The drug has poor penetration into cell membranes
D) The drug is primarily protein-bound in the plasma
E) The drug is poorly absorbed from the GI tract
CORRECT ANSWER: B) The drug distributes extensively into tissues beyond the
vascular compartment
RATIONALE: A volume of distribution (Vd) of 200 L in a 70 kg patient is much larger
than total body water (~42 L) or plasma volume (~3.5 L), indicating the drug
, extensively distributes into tissues beyond the vascular space. This suggests
lipophilic properties, tissue binding, or concentration in specific organs. A high Vd
means a smaller percentage of total drug is in plasma at any given time. Normal
plasma volume is ~3.5 L, total body water is ~42 L, and Vd >200 L indicates
substantial tissue sequestration. Option A would indicate low Vd, C suggests poor
membrane penetration (high Vd contradicts this), D affects the amount in plasma
(independent of Vd interpretation), and E relates to absorption, not distribution.
5) Which phase of pharmacokinetics describes how the body eliminates
drugs?
A) Absorption phase
B) Distribution phase
C) Elimination phase
D) Metabolism phase
E) Excretion phase
CORRECT ANSWER: C) Elimination phase
RATIONALE: The elimination phase encompasses all processes by which the body
removes drugs, including metabolism (biotransformation) and excretion (renal,
biliary, pulmonary, etc.). While metabolism and excretion are individual elimination
pathways, elimination is the overarching phase that describes the decline in plasma
concentration after the drug peaks. Absorption describes drug entry into the body,
distribution describes movement into tissues, and while metabolism and excretion
are components of elimination, the elimination phase as a pharmacokinetic term
refers to the entire process of drug removal from the body.
6) A patient is prescribed a drug with a half-life of 12 hours. How long will it
take to reach steady state?
A) 12 hours
2026/2027 | Final Exam & Pre-Assessment
Questions, Answers & Detailed Rationales |
Updated Study Guide
WGU D116 ADVANCED PHARMACOLOGY 2026/2027
FINAL EXAM & PRE-ASSESSMENT | COMPREHENSIVE QUESTIONS
DOCUMENT OVERVIEW
• This comprehensive study guide contains detailed multiple-choice questions
designed to prepare you for the WGU D116 Advanced Pharmacology final exam
and pre-assessment, with complete rationales for each answer to reinforce
understanding and retention
• Use this material by reviewing questions systematically across all pharmacology
domains, focusing on areas where you score lowest, and referring to detailed
rationales to understand not just the correct answer but the clinical reasoning
behind it
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1-20)
1) Which of the following best describes bioavailability?
A) The amount of drug that reaches the systemic circulation in unchanged form
B) The time it takes for a drug to reach peak concentration
C) The volume of distribution of a drug in the body
D) The rate at which a drug is eliminated from the body
E) The ability of a drug to cross the blood-brain barrier
CORRECT ANSWER: A) The amount of drug that reaches the systemic
circulation in unchanged form
,RATIONALE: Bioavailability is defined as the percentage or fraction of administered
drug dose that reaches systemic circulation in unchanged (active) form. This is a
critical pharmacokinetic parameter that determines drug effectiveness. Option B
describes Tmax (time to maximum concentration), C refers to volume of
distribution, D pertains to clearance/elimination, and E relates to drug distribution
properties. Bioavailability is essential for predicting clinical efficacy and is
influenced by absorption, first-pass metabolism, and route of administration.
2) A 65-year-old male patient has a creatinine clearance of 25 mL/min. Which
pharmacokinetic parameter is most significantly affected in renal
impairment?
A) Absorption rate from the GI tract
B) Clearance and half-life of renally eliminated drugs
C) The volume of distribution of lipophilic drugs
D) The protein binding capacity of serum albumin
E) The first-pass metabolism rate
CORRECT ANSWER: B) Clearance and half-life of renally eliminated drugs
RATIONALE: In patients with renal impairment, the kidneys' ability to eliminate
drugs is compromised, directly reducing total body clearance. This results in
prolonged half-life and increased risk of drug accumulation. Patients with creatinine
clearance of 25 mL/min have severe renal impairment requiring significant dosage
adjustments or alternative medications. While absorption, Vd, protein binding, and
metabolism may be somewhat affected, the primary concern is reduced renal
clearance of active or toxic metabolites. Many drugs require dose reduction or
longer dosing intervals in renal failure.
3) Which of the following processes is responsible for the first-pass effect
when a drug is taken orally?
A) Hepatic metabolism before reaching systemic circulation
,B) Renal filtration at the glomerulus
C) Plasma protein binding in the bloodstream
D) Distribution to peripheral tissues
E) Biliary excretion into the intestines
CORRECT ANSWER: A) Hepatic metabolism before reaching systemic
circulation
RATIONALE: The first-pass effect (first-pass metabolism) occurs when an orally
administered drug is absorbed from the GI tract and transported via the portal
blood to the liver before entering the systemic circulation. Hepatic enzymes
(particularly the cytochrome P450 system) metabolize a portion of the drug,
reducing the amount of unchanged drug reaching systemic circulation. This is why
some drugs have very low oral bioavailability despite good absorption (e.g.,
nitroglycerin, which is given sublingually to bypass this effect). Renal filtration
occurs after systemic absorption, protein binding doesn't eliminate the drug,
distribution occurs after systemic circulation is reached, and biliary excretion is a
separate elimination pathway.
4) A drug has a volume of distribution (Vd) of 200 L in a 70 kg patient. What
does this indicate?
A) The drug is highly water-soluble and remains in the vascular space
B) The drug distributes extensively into tissues beyond the vascular compartment
C) The drug has poor penetration into cell membranes
D) The drug is primarily protein-bound in the plasma
E) The drug is poorly absorbed from the GI tract
CORRECT ANSWER: B) The drug distributes extensively into tissues beyond the
vascular compartment
RATIONALE: A volume of distribution (Vd) of 200 L in a 70 kg patient is much larger
than total body water (~42 L) or plasma volume (~3.5 L), indicating the drug
, extensively distributes into tissues beyond the vascular space. This suggests
lipophilic properties, tissue binding, or concentration in specific organs. A high Vd
means a smaller percentage of total drug is in plasma at any given time. Normal
plasma volume is ~3.5 L, total body water is ~42 L, and Vd >200 L indicates
substantial tissue sequestration. Option A would indicate low Vd, C suggests poor
membrane penetration (high Vd contradicts this), D affects the amount in plasma
(independent of Vd interpretation), and E relates to absorption, not distribution.
5) Which phase of pharmacokinetics describes how the body eliminates
drugs?
A) Absorption phase
B) Distribution phase
C) Elimination phase
D) Metabolism phase
E) Excretion phase
CORRECT ANSWER: C) Elimination phase
RATIONALE: The elimination phase encompasses all processes by which the body
removes drugs, including metabolism (biotransformation) and excretion (renal,
biliary, pulmonary, etc.). While metabolism and excretion are individual elimination
pathways, elimination is the overarching phase that describes the decline in plasma
concentration after the drug peaks. Absorption describes drug entry into the body,
distribution describes movement into tissues, and while metabolism and excretion
are components of elimination, the elimination phase as a pharmacokinetic term
refers to the entire process of drug removal from the body.
6) A patient is prescribed a drug with a half-life of 12 hours. How long will it
take to reach steady state?
A) 12 hours
